AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT00871962 — intervention group
Intervention type: OTHER
Intervention: OXYGEN SUPPLEMENTATION
Description: Patients treated by LTOT, with or without clinically fulfilled criteria for LTOT, with PaO2\<55mmHg or less at rest or during sleeping or less during exercise, if supplemental oxygen is demonstrated to improve the exercise-associated hypoxia. Patients with PaO2 56-59mmHg if they also have dependent edema, pulmonary hypertension or hematocrit higher than 56%
Study NCT00028574 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: gabapentin
Study NCT00028574 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Study NCT03576573 — intervention group
Intervention type: DEVICE
Intervention: PROCOTYL® C
Description: Hip Arthroplasty
Study NCT05551507 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IN10018 in combination with PLD
Description: IN10018 in combination with PLD to treat subjects with platinum-resistant recurrent ovarian cancer
Study NCT02555384 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: crowded drawing task
Description: Marking inverted signs on a sheet where symbols are presented close to one another
Study NCT02555384 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: uncrowded drawing task
Description: Marking inverted signs on a sheet where there is a larger distance between symbols
Study NCT04607369 — intervention group
Intervention type: DEVICE
Intervention: EyeCTester
Description: Smartphone app that allows vision testing
Study NCT03777319 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Spironolactone
Description: Spironolactone will be prescribed for 6 months, after which the family and primary care physician will determine to either remain on spironolactone or transfer to prednisolone.
Study NCT03777319 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Prednisolone
Description: Prednisolone will be prescribed for 6 months as the clinical standard of care.
Study NCT01356199 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: ARTRONAT
Description: Dietary supplement containing Glucosamine, Chondroïtine and manganese. 6 per day for 8 months.
Study NCT01356199 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: PLACEBO
Description: PLACEBO. 6 per day for 8 months.
Study NCT04715698 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: ICG-guided drug selection
Description: anti-hypertensive drug selection based on patient's hemodynamic profiling and physician's experience
Study NCT04715698 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: empirical drug selection
Description: anti-hypertensive drug selection based on physician's experience only
Study NCT01238328 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Conditioning regimen
Description: For sibling full match:~* Busulfan 16 mg/kg >5year - 20 mg/kg \<5year po~* Cyclophosphamide 200 mg/kg iv~For other related full match, sibling or other related with one antigen mismatch and umbilical cord blood:~* Busulfan 16 mg/kg >5year - 20 mg/kg \<5year po~* Cyclophosphamide 200 mg/kg iv~* Antithymocyte globulin (ATG) rabbit (Thymoglobulin) 10 mg/kg or ATG horse (Atgam) 40 mg/kg~For haploidentical:~* Busulfan 16 mg/kg >5year - 20 mg/kg \<5year po~* Cyclophosphamide 200 mg/kg iv~* Fludarabine 160 mg/m\^2
Study NCT01238328 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Graft-versus-host disease (GVHD) prophylaxis
Description: * Cyclosporin A 1.5 mg/kg/day iv from -2, then 3 mg/kg/day iv (from +7 in peripheral blood stem cell transplant (PBSCT) and +11 in Bone marrow transplantation or Umbilical Cord Blood (UCB) transplantation) then 9 mg/kg/day po~* 10 mg/m\^2 iv day +1 then 6 mg/m\^ iv day +3 and +6 (Not for UCBT)
Study NCT01238328 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Stem Cell Transplantation
Description: Patients undergoing Hematopoietic Stem Cell Transplantation from one of below source:~1. Sibling full match~2. Other related full match~3. Sibling or other related with 1 mismatch antigen~4. Cord Blood~5. Haploidentical
Study NCT00992823 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: iron supplementation
Description: 40 doses of 30 mg of ferrous sulfate during a 10-month intervention period
Study NCT00992823 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: iron supplementation
Description: supplementation in two 5-month cycles, each cycle consisting of one month of supplementation (20 workdays) and four months without supplementation.
Study NCT01622777 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rosuvastatin
Description: 20 mg daily of oral rosuvastatin for 12 weeks
Study NCT01622777 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 100 mg of oral placebo with identical appearance, form and size than rosuvastatin, one tablet daily for 12 weeks
Study NCT03245983 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Questionnaire and interview
Description: Cancer patients will answer questionnaires and will be interviewed by a pshychologist to assess their spirituality and quality of life toward their disease
Study NCT01554800 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ACP-501
Description: A single dose infusion
Study NCT02447978 — intervention group
Intervention type: BIOLOGICAL
Intervention: Infanrix
Description: Diphtheria and Tetanus Toxoids and Acellular Pertussis Vaccine Adsorbed Indicated as a 5-dose series in infants and children 6 weeks to 7 years of age.
Study NCT02447978 — intervention group
Intervention type: BIOLOGICAL
Intervention: Pediarix
Description: Diphtheria and Tetanus Toxoids and Acellular Pertussis Ad-sorbed, Hepatitis B (Recombinant) and Inactivated Poliovirus Vaccine Indicated as a 3-dose series in infants born of hepatitis B surface antigen (HBsAg)-negative mothers. PEDIARIX may be given as early as 6 weeks of age through 6 years of age (prior to the 7th birthday).
Study NCT02447978 — intervention group
Intervention type: BIOLOGICAL
Intervention: Kinrix
Description: Diphtheria and Tetanus Toxoids and Acellular Pertussis Ad-sorbed and Inactivated Poliovirus Vaccine
Study NCT02202538 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Indego
Description: Indego
Study NCT02600091 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindfulness-Based Cognitive Therapy
Description: The MBCT intervention is manualised and delivered to groups. The aim of the MBCT intervention is to increase mindfulness skills and to facilitate their use in relation to emotional wellbeing and diabetes self-management. Participants will attend on 8 occasions, once per week, for 2 hours. These meetings will have a standard structure. First, participants will describe their efforts to practice mindfulness at home over the previous week, followed by discussion of an educational topic relevant to the aims of the course. Finally, the group will do a mindfulness practice together, and the home practice for the following week will be set. In-between meetings, participants are asked to practice mindfulness by listening to an audio file or CD for about 30 minutes per day.
Study NCT00328861 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Natural Killer (NK) Lymphocytes
Description: Thirty minutes infusion of natural killer (NK) cells 2 days after last dose of chemotherapy.
Study NCT00328861 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: IL-2
Description: IL-2 720,000 IU/kg/intravenous every 8 hours for up to 5 days.
Study NCT00328861 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Cyclophosphamide 60 mg/kg/day intravenous on days -8 and -7.
Study NCT00328861 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: Fludarabine 25 mg/m\^2 day intravenous on days -6 through -2.
Study NCT01819350 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: G1, G2 and G3
Description: Nutritional, respiratory and endocrine group applicated 12 subjects
Study NCT01819350 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: G4 and G5
Description: Application of trhree pediadic medidines of antibiotic group on dental biofilm 12 subjects
Study NCT04294147 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Galcanezumab
Description: Administered SC
Study NCT04294147 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Erenumab
Description: Administered SC
Study NCT04271033 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Carotid Artery Stenting
Description: Carotid artery stenting according to local clinical experience and ESC/ESVS guidelines using exclusively CGuard™, MicroNet covered stent under proximal or distal intraprocedural cerebral protection according to tailored CAS algorithm.
Study NCT03252223 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Recombinant Follicle Stimulating Hormone
Description: A modified dose-response study will be done using recombinant FSH (r-FSH), injected sc for 3 days at any one dose. r-FSH will be administered at weight-adjusted doses equivalent to 37.5, 75, and 150 IU based on an average weight of 70 kg, which approximates the weight of the average woman in the United States according to the Centers for Disease Control. Therefore, the actual dose of r-FSH will be 0.53 IU/kg for the 37.5 dose group. Accordingly, r-FSH will be repeated at doses of 1.1 IU/kg and 2.2 IU/kg that are equivalent to 75 and 150 IU for a 70 kg subject. Each FSH stimulation test will be assigned randomly and be separated by an interval of 8 weeks.
Study NCT04118595 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Educational Video
Description: Educational Video: Development of the original video was funded by the John A. Hartford Foundation and used a systematic approach that included a review of literature and current pain management guidelines and input from emergency physicians, geriatricians, and experts in pharmacology, physical therapy, and risk communication. The video offers information about the pharmacologic management of acute musculoskeletal pain (MSP) and recovery-promoting behaviors. Each video section is followed by a multiple-choice question to promote interaction and reinforce learning. The actress for the 13-minute video is a 56-year-old mixed-race woman who presents herself as a healthcare provider. The video script was developed for a grade level 5.5 and will be shown to the patient within 24 hours of the acute care visit. A link to the video is emailed or texted to the patient.
Study NCT04118595 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Telecare
Description: Telecare will be provided via a protocol-guided phone call from a nurse care manager 48-72 hours after discharge from the ED or orthopedic urgent care. The call is designed to support patient decision-making regarding analgesics and behaviors following the content presented in the video. Topics covered in the call will include discussion of goals and priorities the patient has for their pain management, current prescriptions and analgesic use (and adjustments if needed), non-pharmacologic methods of pain management, warnings about potential side effects, current healthcare utilization, and open-ended questions to address additional patient care needs. Conversations will be guided by a shared decision making framework in which the nurse suggests pain management options, discusses their pros and cons, and actively elicits feedback from the patient. The telecare call is designed to last 15 minutes.
Study NCT04118595 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Correspondence with Primary Care Provider
Description: Following the telecare conversation, a note will be sent directly to the patient's primary care provider using a secure email or an electronic message that includes: 1) The date, time, location and reason for the index visit; (2) Results of diagnostics studies; (3) Discharge prescriptions/ recommendations; (4) A summary of and link to the video, explaining the emphasis on patient knowledge and SDM; (5) A summary of the telecare conversation; and (6) Encouragement for follow-up. PCPs will be asked to confirm receipt of this message.
Study NCT01887353 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ranolazine
Description: Patients will take ranolazine 1000 mg tablets twice daily
Study NCT01887353 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo pill manufactured to mimic ranolazine 1000 mg tablets. Patients will be instructed to take two pills a day.
Study NCT04275024 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Calcipotriol ointment
Description: The topical treatment in the study was calcipotriol ointment(Dovonex;LEO Laboratories Ltd, Ireland) twice daily for 12 weeks.
Study NCT04275024 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PSORI-CM01 Granule
Description: PSORI-CM01#YXBCM01# granule 5.5g os once a day for 12weeks.
Study NCT04275024 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: adipose-derived multipotent mesenchymal stem cells
Description: AD-MSCs(adipose-derived multipotent mesenchymal stem cells) were infused intravenously at a dose of 2 million cells/kg
Study NCT02255942 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Ferric Pyrophosphate and Zinc Oxide
Description: Rice fortified with Ferric Pyrophosphate and Zinc Oxide (ZnO)
Study NCT01622387 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Coronary artery bypass (CABG) surgery using a radial arterial conduit
Description: Use of radial artery as a bypass conduit/graft to the left circumflex coronary artery region of the heart in CABG surgery
Study NCT01622387 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Coronary artery bypass surgery using a long saphenous vein conduit
Description: Use of long saphenous vein as a graft/conduit vessel to the left circumflex coronary artery region of the heart in CABG surgery
Study NCT02220712 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OPC-14597 IMD
Description: Administration by injection into the deltoid muscle for a total of 5 doses of 400 mg in 4-week intervals
Study NCT02255942 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Ferrous sulfate
Description: Rice fortified with Ferrous Sulfate (ZnSO4)
Study NCT03796351 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MT10107
Description: Subjects will be administered a single equivalent dose of MT10107 and Botox® by intramuscular injection to the EDB muscles of contralateral feet. Five cohorts of eligible subjects will be studied; Group A (2 U dose), Group B (5 U dose), Group C (10 U dose), Group D (20 U dose) and Group E (30 U dose).~The foot in which each drug is to be administered (i.e. left or right) will be assigned in a randomized manner.
Study NCT03796351 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Botox
Description: Subjects will be administered a single equivalent dose of MT10107 and Botox® by intramuscular injection to the EDB muscles of contralateral feet. Five cohorts of eligible subjects will be studied; Group A (2 U dose), Group B (5 U dose), Group C (10 U dose), Group D (20 U dose) and Group E (30 U dose).~The foot in which each drug is to be administered (i.e. left or right) will be assigned in a randomized manner.
Study NCT02255942 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Ferric Pyrophosphate and Zinc Sulfate
Description: Rice fortified with Ferric Pyrophosphate and Zinc Sulfate
Study NCT00604890 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: API 31510 3% Topical Cream
Description: Topical treatment 3% active cream applied to the lesion
Study NCT00604890 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: API 31510 3% Topical Cream
Description: Topical treatment 3% active cream applied to the lesion
Study NCT00604890 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: API 31510 1.5% Topical Cream
Description: Topical treatment 1.5% active cream applied to the lesion
Study NCT00604890 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Topical treatment placebo applied to the lesion
Study NCT01881568 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tranexamic Acid
Description: Topical administration: 3g of Tranexamic Acid in 100mL of normal saline (0.9% sodium chloride)
Study NCT01881568 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tranexamic Acid
Description: Intravenous administration of two dosis of Tranexamic Acid (15mg/kg of Tranexamic Acid in 100mL of normal saline each)
Study NCT02820025 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: doxapram
Study NCT02820025 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: saline
Study NCT01915979 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Plasma rich in growth factors (PRGF)
Study NCT01915979 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Celestone cronodose (Bethametasone)
Study NCT03954262 — intervention group
Intervention type: BEHAVIORAL
Intervention: observation of propofol ANS response
Description: received an induction bolus or TCI infusion of propofol
Study NCT00061932 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: irinotecan
Description: Given IV
Study NCT02656407 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Ultrasound device
Description: Ultrasensitive Doppler acquisition obtained with the Aixplorer ultrasound device
Study NCT02255942 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Ferric Pyrophosphate
Description: Rice fortified with Ferric Pyrophosphate
Study NCT03166098 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Cognitive Function Assessments
Description: The NIMH-Measurement and Treatment Research to Improve Cognition in Schizophrenia (MATRICS) is a consensus battery that is considered state-of-the art in the evaluation of cognitive skills for schizophrenia research.(Burton et al., 2013, Harvey, 2014) The complete cognitive battery takes about one hour to administer, and is comprised of 10 subtests measuring seven essential domains of function, with very good reliability and validity.(Nuechterlein 2008, August et al., 2012) The MATRICS subtests have been incorporated into the cognitive battery described below, with supplementary subtests included where indicated within each domain.
Study NCT02779166 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Celecoxib
Description: Received 400mg celecoxib prior to surgery
Study NCT00745433 — intervention group
Intervention type: DRUG
Intervention: repaglinide
Description: Start dose and frequency at the discretion of the physician following clinical practice
Study NCT00745433 — intervention group
Intervention type: DRUG
Intervention: metformin
Description: Start dose and frequency at the discretion of the physician following clinical practice
Study NCT03262441 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mycophenolate Mofetil 500Mg Tab
Description: 500 mg once daily for one week. If tolerating the drug, then initiate twice daily for 22 months
Study NCT04000074 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Telephonic Services
Description: Provides linkage services to local programs that address the social determinants of health remotely via phone, email and/or fax
Study NCT04000074 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: In-Person Services
Description: Provides linkage services to local programs that address the social determinants of health directly to the client during face-to-face visits as well as remotely via phone, email, etc.
Study NCT04559048 — intervention group
Intervention type: DRUG
Intervention: FK506
Description: FK506 (tacrolimus), a calcineurin inhibitor, is widely used as an immunosuppressant to lower the risk of organ rejection after organ transplantation
Study NCT02090517 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Pulsed Dye Laser
Description: Pulsed dye laser treatments will be performed with a 595 nanometer wavelength, 20 millisecond pulse duration, at 10 Joules/cm2, with a 10 millimeter spot size.
Study NCT02090517 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Long Pulsed Alexandrite Laser
Description: Alexandrite laser will be used with a 755 nanometer wavelength, 40 millisecond pulse duration, at 88Joules/cm2, with a 6 millimeter spot size.
Study NCT02090517 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Pulsed Dye Laser Plus Nd:YAG Laser
Description: The Cynergy with MultiPlex will be used with a multiplex mode system with a pulse dye laser at 585 nanometer wavelength, 20 milliseconds pulse duration, at 7 Joules/cm2 with a 7 millimeter spot size, with a short delay, followed by a Nd:YAG 1064 nanometer wavelength, 20 millisecond pulse duration, at 50 Joules/cm2 with a 7 millimeter spot size.
Study NCT02090517 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Electrodesiccation
Description: A curette is used to scrape off the cancer down to the dermis. The scraping is then paused while an electrosurgical device like a hyfrecator is used next. Electrodesiccation is performed over the raw surgical ulcer to denature a layer of the dermis and the curette is used again over the surgical ulcer to remove denatured dermis down to living tissue.
Study NCT01023646 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Carbohydrate + Protein
Description: Light Tuna Packed in water.
Study NCT01023646 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Carbohydrate + Fat
Description: Butter
Study NCT01023646 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Fiber
Description: Unrefined Carbohydrate
Study NCT01023646 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Carbohydrate load
Description: Carbohydrate
Study NCT04666194 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Cold forceps
Study NCT04666194 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Cold snare